Schizophrenia Research

Editorial Board
pp. CO2-CO2(1)

Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis
pp. 89-96(8)
Authors: Heresco-Levy U.; Javitt D.C.

Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study
pp. 97-100(4)
Authors: Louza M.R.; Marques A.P.; Elkis H.; Bassitt D.; Diegoli M.; Gattaz W.F.

Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia
pp. 101-113(13)
Authors: Harvey P.D.; Meltzer H.; Simpson G.M.; Potkin S.G.; Loebel A.; Siu C.; Romano S.J.

Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample
pp. 115-124(10)
Authors: Kavanagh D.J.; Waghorn G.; Jenner L.; Chant D.C.; Carr V.; Evans M.; Herrman H.; Jablensky A.; McGrath J.J.

First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol
pp. 125-135(11)
Authors: HGDH Research Group; Green A.I.; Tohen M.F.; Hamer R.M.; Strakowski S.M.; Lieberman J.A.; Glick I.; Scott Clark W.

Changes in caudate volume after exposure to atypical neuroleptics in patients with schizophrenia may be sex-dependent
pp. 137-142(6)
Authors: Heitmiller D.R.; Nopoulos P.C.; Andreasen N.C.

Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia
pp. 143-150(8)
Authors: Buckley P.F.; Goldstein J.M.; Emsley R.A.

Differential effects of long-term treatment with clozapine or haloperidol on GABA_A receptor binding and GAD₆₇ expression
pp. 151-157(7)
Authors: Zink M.; Schmitt A.; May B.; Muller B.; Demirakca T.; Braus D.F.; Henn F.A.

Clozapine's effects on body weight and resting metabolic rate: a case series
pp. 159-162(4)
Authors: Procyshyn R.M.; Chau A.; Tse G.

Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications
pp. 163-167(5)
Authors: Lasser R.A.; Mao L.; Gharabawi G.

Sex, ethnicity, and antipsychotic medication use in patients with psychosis
pp. 169-175(7)
Authors: Arnold L.M.; Strakowski S.M.; Schwiers M.L.; Amicone J.; Fleck D.E.; Corey K.B.; Farrow J.E.

Secretin for refractory schizophrenia
pp. 177-181(5)
Authors: Sheitman B.B.; Knable M.B.; Jarskog L.F.; Chakos M.; Boyce L.H.; Early J.; Lieberman J.A.

Secretin in a patient with treatment-resistant schizophrenia and prominent autistic features
pp. 183-186(4)
Authors: Alamy S.S.; Jarskog L.F.; Sheitman B.B.; Lieberman J.A.

The effects of olanzapine on sensory gating in healthy participants
pp. 187-189(3)
Authors: Carroll C.A.; O'Donnell B.F.; Shekhar A.; Hetrick W.P.

Olanzapine-induced QTc prolongation in a patient with Wolff-Parkinson-White syndrome
pp. 191-192(2)
Authors: Su K.-P.; Lane H.-Y.; Chuang C.-L.; Chen K.-P.; Shen W.W.

An association study of the neurotensin receptor gene with schizophrenia and clozapine response
pp. 193-195(3)
Authors: Huezo-Diaz P.; Arranz M.J.; Munro J.; Osborne S.; Makoff A.; Kerwin R.W.; Austin J.; O'Donovan M.

Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients
pp. 197-198(2)
Authors: Mauri M.C.; Volonteri L.S.; Fiorentini A.; Invernizzi G.; Nerini T.; Baldi M.; Bareggi S.R.

Treatment of tardive pharyngolaryngeal dystonia with olanzapine
pp. 199-200(2)
Authors: Havaki-Kontaxaki B.J.; Kontaxakis V.P.; Christodoulou G.N.

Improvement in social cognition in patients with schizophrenia associated with treatment with olanzapine
pp. 201-202(2)
Authors: Littrell K.H.; Petty R.G.; Hilligoss N.M.; Kirshner C.D.; Johnson C.G.

Author index
pp. 205-206(2)

Keyword index
pp. 207-210(4)